<DOC>
	<DOCNO>NCT00197249</DOCNO>
	<brief_summary>To evaluate immunogenicity , reactogenicity safety Hepatyrix compare concomitant administration Typherix Havrix , compare administration monovalent vaccine , Havrix Typhim Vi . Furthermore , study evaluate persistence anti-Vi anti-HAV antibody 36 month administration first dose study vaccine .</brief_summary>
	<brief_title>Comparative Study Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix Havrix+Typherix Tiphim Vi , Compare Reactogenicity &amp; Immunogenicity</brief_title>
	<detailed_description>Compare reactogenicity &amp; immunogenicity GSK Biologicals ' combine Vi polysaccharide typhoid vaccine &amp; inactivate hepatitis A vaccine , Hepatyrix , elicit GSK Biologicals ' hepatitis A vaccine , Havrix administer singly concomitantly GSK Biologicals ' Vi polysaccharide vaccine , Typherix , &amp; elicit Aventis Pasteur 's monovalent Vi polysaccharide vaccine , Typhim Vi , administer intramuscularly healthy subject age 18-65 yr .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion Written inform consent obtain subject prior entry study . Free obvious health problem establish medical history clinical examination enter study . Seronegative antiHAV antibody . If subject female , must nonchildbearing potential , i.e. , either surgically sterilize one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution ( e.g. , intrauterine contraceptive device ; oral contraceptive ; diaphragm condom combination contraceptive jelly , cream foam ; Norplant® DepoProvera® ) 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Subjects receive study vaccine 36 month earlier . Exclusion criterion Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . ( For corticosteroid , mean prednisone , equivalent , &gt; = 0.5 mg/kg/day . Inhaled topical steroid allowed. ) . Planned administration/Administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History chronic alcohol consumption and/or intravenous drug abuse . Previous vaccination hepatitis A . Previous vaccination typhoid fever . History hepatitis A . Previous diagnosis , confirm physician , Salmonella typhi infection . History nonresponse hepatitis A typhoid vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhoea , mild upper respiratory infection without lowgrade febrile illness , i.e. , axillary temperature &lt; 99.5 °F ( 37.5 °C ) Female plan become pregnant primary study period ( Month 7 ) . Pregnant lactate female . Planned travel area high endemicity hepatitis A and/ typhoid fever primary study period ( Month 7 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis A &amp; B</keyword>
	<keyword>Typhoid</keyword>
</DOC>